Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback